The Biospecimen and Pathology Core of the Breast SPORE is responsible for accessioning and processing new biospecimens for the Breast SPORE Biospecimen Repository and to make those specimens available for use in the four SPORE main projects and very likely for the Developmental Research and Career Development Programs. Biospecimens will also be made available to other intra- and extra-mural investigators engaged in breast cancer translational research. Requests for biospecimens will be taken under consideration by the Breast SPORE Operations Committee, with a heavy emphasis on scientific merit and on availability of specimens and their associated data needed for analysis. Input from the Biostatistics and Patient Registry Core is included in the evaluation of requests for tissues. The Pathology Team of the Biospecimen Core will provide detailed annotations in the Breast Pathology Database for frozen and formalin-fixed paraffin-embedded tissues from selected cohorts of patients to support SPORE projects and additional projects for which the Breast Biospecimen Repository has provided tissues. The Core pathology team will also interpret IHC staining. The Biospecimen and Pathology Core will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing Shared Resource to process blood samples to provide genomic DNA and serum aliquots, and with the Tissue and Cell Molecular Analysis Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state of the art equipment. New immunostaining assays will be developed by the Biospecimen and Pathology Core, as well as construction of cell line tissue microarrays to screen and test antibodies for immunostaining formalin-fixed, paraffin-embedded tissues.

Public Health Relevance

The Biospecimen and Pathology Core provides the biospecimens (frozen tissue, FFPE tissue, tissue microarrays and cell line microarrays, blood, serum, DNA, and RNA), pathology annotations, histological services, and pathology support necessary to support the projects of the Mayo Clinic Breast Cancer SPORE as well as other breast cancer translational research projects. The Core also provides histology-related services, such as sectioning, immunostaining, antibody optimization and characterization, and digital imaging. Core pathologists provide IHC interpretations. These functions are essential to most translational research, including the specific projects included in this SPORE proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-07
Application #
8555342
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2005-09-21
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2012
Total Cost
$251,038
Indirect Cost
$77,257
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Tu, Xinyi; Kahila, Mohamed M; Zhou, Qin et al. (2018) ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Mol Cancer Ther 17:2462-2472
Athreya, Arjun P; Gaglio, Alan J; Cairns, Junmei et al. (2018) Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer. IEEE Trans Nanobioscience 17:251-259
Wiese, Elizabeth K; Hitosugi, Taro (2018) Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect. Front Cell Dev Biol 6:79
Frank, Ryan D; Winham, Stacey J; Vierkant, Robert A et al. (2018) Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer 124:3319-3328
Degnim, Amy C; Winham, Stacey J; Frank, Ryan D et al. (2018) Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol 36:1840-1846
Ohmine, Seiga; Salisbury, Jeffrey L; Ingle, James et al. (2018) Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep 39:1725-1730
Kourtidis, Antonis; Anastasiadis, Panos Z (2018) Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol 54:30-36
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Ho, Ming-Fen; Lummertz da Rocha, Edroaldo; Zhang, Cheng et al. (2018) TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ?B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther 365:700-710
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574

Showing the most recent 10 out of 473 publications